Abstract

Interferon Regulatory Factor 5 (IRF5) is one of nine members of the IRF family of transcription factors. Although initially discovered as a key regulator of the type I interferon and pro-inflammatory cytokine arm of the innate immune response, IRF5 has now been found to also mediate pathways involved in cell growth and differentiation, apoptosis, metabolic homeostasis and tumor suppression. Hyperactivation of IRF5 has been implicated in numerous autoimmune diseases, chief among them systemic lupus erythematosus (SLE). SLE is a heterogeneous autoimmune disease in which patients often share similar characteristics in terms of autoantibody production and strong genetic risk factors, yet also possess unique disease signatures. IRF5 pathogenic alleles contribute one of the strongest risk factors for SLE disease development. Multiple models of murine lupus have shown that loss of Irf5 is protective against disease development. In an attempt to elucidate the regulatory role(s) of IRF5 in driving SLE pathogenesis, labs have begun to examine the function of IRF5 in several immune cell types, including B cells, macrophages, and dendritic cells. A somewhat untouched area of research on IRF5 is in T cells, even though Irf5 knockout mice were reported to have skewing of T cell subsets from T helper 1 (Th1) and T helper 17 (Th17) toward T helper 2 (Th2), indicating a potential role for IRF5 in T cell regulation. However, most studies attributed this T cell phenotype in Irf5 knockout mice to dysregulation of antigen presenting cell function rather than an intrinsic role for IRF5 in T cells. In this review, we offer a different interpretation of the literature. The role of IRF5 in T cells, specifically its control of T cell effector polarization and the resultant T cell-mediated cytokine production, has yet to be elucidated. A strong understanding of the regulatory role(s) of this key transcription factor in T cells is necessary for us to grasp the full picture of the complex pathogenesis of autoimmune diseases like SLE.

Highlights

  • T cells are responsible for balancing a variety of regulatory and effector functions

  • In systemic lupus erythematosus (SLE) studies performed in humans and mice, some of the likely cytokine inflammatory mediators and immunomodulatory agents identified as participating in disease development include interferon (IFN)-α, IFN-γ, tumor necrosis factor (TNF), interleukin (IL)1, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17, IL21 and transforming growth factor (TGF)-β [5,6,7,8]

  • We propose a novel DEF6-Interferon Regulatory Factor 5 (IRF5)-T-bet regulatory mechanism that controls T helper 1 (Th1) effector T cell polarization

Read more

Summary

Introduction

T cells are responsible for balancing a variety of regulatory and effector functions. STAT4 itself can act as a potent transcriptional repressor of genes that would normally support Th2 differentiation (i.e., GATA3) and acts in concert with T-bet to promote the positive feedback loop resulting in increased IFN-γ production.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call